The AHNAK Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited cell population in which the endogenous AHNAK gene has been disrupted through targeted genome engineering. This polyclonal knockout product provides a heterogeneous pool of HeLa-derived cells harboring diverse gene-disruption events, enabling robust loss-of-function studies without the need for single-cell cloning. The polyclonal format captures a representative spectrum of genetic modifications, making it suitable for pooled phenotypic screens and bulk biochemical analyses. Researchers can employ these cells to interrogate AHNAK-dependent processes in a human epithelial tumor background, offering a versatile tool for signal transduction and cancer biology investigations.
The host cell line, HeLa, is a widely established model of human cervical adenocarcinoma that has been instrumental in revealing fundamental mechanisms of cell cycle regulation, oncogenesis, and cytoskeletal dynamics. Derived from a cervical carcinoma, HeLa cells retain hallmark features of epithelial cancers, including aberrant proliferation and anchorage-independent growth. Their robust growth in culture and well-characterized biology make them a reliable platform for examining gene function in cancer-relevant contexts. By introducing an AHNAK knockout into this background, the resultant polyclonal population empowers detailed dissection of tumor cell behavior, particularly adhesion, migration, and calcium responsiveness.
AHNAK encodes an exceptionally large scaffold protein that orchestrates the interplay between calcium signaling, actin cytoskeleton reorganization, and membrane repair. Activated by calcium/calmodulin, CaMKII, and protein kinase C, AHNAK nucleates multiprotein assemblies at the plasma membrane and cytoskeletal interface. It directly interacts with actin, ERM proteins, S100B, and Annexin A2, thereby facilitating cellular responses to mechanical and calcium stimuli. Through these interactions, AHNAK bridges calcium influx to downstream effectors that govern actin remodeling, cell?Cmatrix adhesion, and membrane resealing. This scaffolding function positions AHNAK as a central node linking extracellular cues to cytoskeletal restructuring and plasma membrane integrity.
In HeLa cells, AHNAK contributes to the maintenance of epithelial morphology and the coordination of calcium-dependent processes such as cell spreading and wound healing. Loss of AHNAK disrupts the association of the actin cytoskeleton with membrane repair complexes, leading to impaired membrane resealing after mechanical injury and altered cell adhesion. Consequently, AHNAK knockout HeLa cells exhibit reduced migratory capacity and invasiveness, reflecting the scaffold’s role in cancer cell dynamics. Moreover, disruption of AHNAK-mediated signaling may compromise the regulation of ERM proteins and Annexin A2, highlighting the model’s utility for probing the molecular underpinnings of cervical adenocarcinoma progression.
This polyclonal knockout product is ideally suited for a broad array of functional studies, including cancer cell migration and invasion assays, calcium imaging, membrane repair investigations, and drug target validation. Compatible techniques such as Western blotting, immunofluorescence, co-immunoprecipitation, wound healing, Transwell invasion assays, and RNA sequencing enable thorough characterization of AHNAK-dependent phenotypes. The cells support both mechanistic dissection of the AHNAK interactome and translational research aimed at targeting calcium?Ccytoskeletal signaling in metastatic disease. For additional product details and technical support, please contact Ascent Research.
